230 related articles for article (PubMed ID: 31105270)
41. Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma.
Naruse M; Young WF
Lancet; 2024 Mar; 403(10431):1001-1003. PubMed ID: 38402884
[No Abstract] [Full Text] [Related]
42. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Powers JF; Korgaonkar PG; Fliedner S; Giubellino A; Pacak K; Sahagian GG; Tischler AS
PLoS One; 2014; 9(2):e87807. PubMed ID: 24516563
[TBL] [Abstract][Full Text] [Related]
43. Long-term prognosis of patients with pediatric pheochromocytoma.
Bausch B; Wellner U; Bausch D; Schiavi F; Barontini M; Sanso G; Walz MK; Peczkowska M; Weryha G; Dall'igna P; Cecchetto G; Bisogno G; Moeller LC; Bockenhauer D; Patocs A; Rácz K; Zabolotnyi D; Yaremchuk S; Dzivite-Krisane I; Castinetti F; Taieb D; Malinoc A; von Dobschuetz E; Roessler J; Schmid KW; Opocher G; Eng C; Neumann HP
Endocr Relat Cancer; 2014 Feb; 21(1):17-25. PubMed ID: 24169644
[TBL] [Abstract][Full Text] [Related]
44. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
[TBL] [Abstract][Full Text] [Related]
45. Niche for polyamine inhibition in treatment of metastatic pheochromocytoma and paraganglioma.
Ghayee HK; Hatch H; Bergeron RJ; Hadrava Vanova K; Pacak K; Tevosian S
Eur J Clin Invest; 2024 May; 54(5):e14162. PubMed ID: 38381501
[No Abstract] [Full Text] [Related]
46. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract][Full Text] [Related]
47. Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis.
Bugalho MJ; Silva AL; Domingues R
Fam Cancer; 2015 Dec; 14(4):603-7. PubMed ID: 26071763
[TBL] [Abstract][Full Text] [Related]
48. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
49. Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients.
Castellano M; Mori L; Giacchè M; Agliozzo E; Tosini R; Panarotto A; Cappelli C; Mulatero P; Cumetti D; Veglio F; Agabiti-Rosei E
Ann N Y Acad Sci; 2006 Aug; 1073():156-65. PubMed ID: 17102082
[TBL] [Abstract][Full Text] [Related]
50. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
51. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996
[TBL] [Abstract][Full Text] [Related]
52. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
53. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
54. Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment.
Facchin C; Perez-Liva M; Garofalakis A; Viel T; Certain A; Balvay D; Yoganathan T; Woszczyk J; De Sousa K; Sourdon J; Provost J; Tanter M; Lussey-Lepoutre C; Favier J; Tavitian B
Theranostics; 2020; 10(8):3518-3532. PubMed ID: 32206105
[No Abstract] [Full Text] [Related]
55. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
56. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.
McInerney-Leo AM; Marshall MS; Gardiner B; Benn DE; McFarlane J; Robinson BG; Brown MA; Leo PJ; Clifton-Bligh RJ; Duncan EL
Clin Endocrinol (Oxf); 2014 Jan; 80(1):25-33. PubMed ID: 24102379
[TBL] [Abstract][Full Text] [Related]
57. Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study.
Luiz HV; Tanchee MJ; Pavlatou MG; Yu R; Nambuba J; Wolf K; Prodanov T; Wesley R; Adams K; Fojo T; Pacak K
Clin Endocrinol (Oxf); 2016 Jul; 85(1):62-9. PubMed ID: 26998836
[TBL] [Abstract][Full Text] [Related]
58. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
[TBL] [Abstract][Full Text] [Related]
59. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
[TBL] [Abstract][Full Text] [Related]
60. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
